乳腺癌放疗中心脏剂量体积参数与健康相关生活质量的关系:RadComp试验分析
该分析纳入1160例RadComp试验乳腺癌患者,比较质子与光子放疗对心脏亚结构的剂量,并评估放疗后6个月内健康相关生活质量变化及其与剂量体积参数的关系。质子放疗的心脏平均剂量显著低于光子放疗,患者报告结局总体良好,未发现心脏剂量体积参数与早期生活质量结局相关。
要点
- 质子放疗全心脏平均剂量0.89 Gy(RBE)显著低于光子2.99 Gy。
- 患者报告的心脏相关症状指标各时间点均良好,≥3级毒性不常见。
- 未发现心脏剂量体积参数与放疗后6个月内心脏相关生活质量相关。
核心结论
- 质子放疗较光子放疗显著降低心脏及心脏亚结构剂量,但未发现心脏剂量体积参数与早期心脏相关生活质量结局相关。
研究设计与样本
- 基于RadComp实用随机临床试验的分析,纳入1160例有全部心脏亚结构剂量体积直方图参数且完成基线及至少1次随访生活质量评估的乳腺癌患者。
- 比较质子与光子放疗对心脏亚结构的剂量,评估基线至放疗后6个月生活质量变化,并分析剂量体积参数与心脏相关生活质量变化的关联。
主要发现
- 质子放疗全心脏平均剂量为0.89 Gy(RBE)(Q1-Q3,0.49-1.39),光子放疗为2.99 Gy(Q1-Q3,1.60-4.61),P< .001。
- 左心室、左心房和左前降支的平均剂量在质子组也显著更低(P< .001)。
- PRO-CTCAE各项指标在所有时间点均良好,仅观察到轻微变化,所有指标≥3级毒性不常见(≤5.5%)。
- 按治疗臂或侧别评估,放疗后6个月内未发现任何剂量体积直方图参数与任何心脏相关生活质量结局显著相关。
关键数值与推荐
- 心脏亚结构包括全心脏、左心室、右心室、左心房、右心房和左前降支。
- 暴露参数包括0.03 cm³剂量、最大剂量、平均剂量和接受特定剂量的体积百分比。
- 生活质量指标包括PROMIS疲劳、PRO-CTCAE气短、胸痛、胸闷和心绞痛。
临床怎么用
- 质子放疗可显著降低乳腺癌患者心脏及心脏亚结构剂量,但早期心脏相关生活质量未见与剂量体积参数的关联。
- 患者报告的心脏相关症状总体良好,≥3级毒性不常见,支持质子放疗在心脏剂量方面的优势。
局限性
- 分析仅纳入有完整剂量体积直方图参数和随访生活质量数据的患者,可能存在选择偏倚。
- 随访时间限于放疗后6个月,无法评估长期生活质量结局。
- 未发现剂量体积参数与生活质量结局的关联,可能受随访时间短和事件数少限制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Relationships between radiation therapy (RT) dose to cardiac substructures and patient-reported outcomes, as assessed by health-related quality of life (HRQOL), remain unknown. We sought to: (1) compare RT dose to cardiac substructures in patients treated with proton versus photon RT on the Radiotherapy Comparative Effectiveness (RadComp) pragmatic randomized clinical trial, which compared proton versus photon RT in breast cancer; (2) evaluate whether there were changes in HRQOL outcomes from baseline to 6 months following RT; and (3) determine the potential associations between radiation dose-volume histogram (DVH) parameters and changes in cardiac-related HRQOL. METHODS AND MATERIALS: This analysis included 1160 RadComp participants with available radiation DVH metrics for all cardiac substructures who completed baseline and ≥1 follow-up HRQOL over the 6 months post-RT. Cardiac substructures included the whole heart, left ventricle, right ventricle, left atrium, right atrium, and left anterior descending artery; exposures of interest included dose to 0.03 cm3, maximum dose, mean dose, and percent volume receiving a specified dose. HRQOL measures that we hypothesized could provide some insights into cardiac symptoms included Patient-Reported Outcomes Measurement Information System (PROMIS) fatigue, Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) shortness of breath and chest pain, chest tightness, and angina. RESULTS: The mean dose to the whole heart was lower with protons, 0.89 Gy(relative biological effectiveness (RBE)) (Q1-Q3, 0.49-1.39), compared with photons 2.99 Gy (Q1-Q3, 1.60-4.61) (P< .001), as was the mean dose to the left ventricle, left atrium, and left anterior descending artery (P < .001). PRO-CTCAE measures were favorable at all time points with only modest changes observed, and grade ≥3 toxicity was uncommon (≤5.5%) for all measures. No DVH metrics were significantly associated with any cardiac-related HRQOL outcomes over the 6 months post-RT when evaluated by treatment arm or laterality. CONCLUSIONS: Proton RT generally conferred significantly lower doses to the heart and cardiac substructures compared with photon RT. PRO-CTCAE measures were favorable overall. No cardiac DVH parameters were associated with early HRQOL outcomes.
引用
- Wright JL, Ko K, Kenworthy W, et al. Associations Between Cardiac Radiation Dose-Volume Metrics and Health-Related Quality of Life for Patients With Breast Cancer on the RadComp Trial. Int J Radiat Oncol Biol Phys. 2026. PMID: 42479004. doi:10.1016/j.ijrobp.2026.06.3055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。